Download PDF
Semin Thromb Hemost 2007; 33(6): 582-587
DOI: 10.1055/s-2007-985754
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Venous Thrombosis at Unusual Sites and the Role of Thrombophilia

Federico Lussana1 , 2 , Francesco Dentali3 , Walter Ageno3 , Pieter W. Kamphuisen1
  • 1Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • 2Unit of Hematology and Thrombosis Department of Medicine, Surgery and Dentistry Ospedale San Paolo, University of Milano, Milano, Italy
  • 3Department of Clinical Medicine, University of Insubria, Varese, Italy
Further Information

Publication History

Publication Date:
04 September 2007 (online)

    Permissions and Reprints

ABSTRACT

Thrombophilia includes multiple inherited and acquired risk factors that determine a shift in the balance of procoagulant and anticoagulant factors promoting hypercoagulability, which is associated with an increased risk of venous thromboembolism (VTE). VTE is characterized by more common clinical manifestations, such as deep vein thrombosis of the lower limbs or pulmonary embolism, and less common clinical manifestations affecting cerebral, splanchnic, upper limbs, and retinal veins. The role of inherited thrombophilia in the pathogenesis of VTE at unusual sites is better established in cerebral vein thrombosis, but its role is less clear in splanchnic, upper limbs, and retinal vein thrombosis, in which acquired risk factors such as malignancy, central venous catheters, or systemic diseases also are frequently involved. The complex interactions between different inherited and acquired thrombophilic risk factors and their relationship with endothelium may be considered the pathophysiologic key of underlying phenotypic manifestations of thrombosis. The understanding of these mechanisms might facilitate diagnosis with appropriate investigations and improve therapeutic decision making.

KEYWORDS

Thrombophilia - thrombosis of the upper extremities - retinal vein occlusion - cerebral vein thrombosis - splanchnic vein thrombosis

REFERENCES

  • 1 Infante-Rivard C, David M, Gauthier R, Rivard G E. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study.  N Engl J Med. 1991;  325 1063-1066
    PubMedGoogle Scholar
  • 2 De Stefano V, Fiorini A, Rossi E et al.. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.  J Thromb Haemost. 2007;  5 708-714
    CrossrefPubMedGoogle Scholar
  • 3 Primignani M, Martinelli I, Bucciarelli P et al.. Risk factors for thrombophilia in extrahepatic portal vein obstruction.  Hepatology. 2005;  41 603-608
    CrossrefPubMedGoogle Scholar
  • 4 Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis.  Blood. 2006;  107 2766-2773
    CrossrefPubMedGoogle Scholar
  • 5 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states.  N Engl J Med. 1999;  340 1555-1564
    CrossrefPubMedGoogle Scholar
  • 6 Joffe H V, Kucher N, Tapson V F, Goldhaber S Z. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients.  Circulation. 2004;  110 1605-1611
    CrossrefPubMedGoogle Scholar
  • 7 Hill S L, Berry R E. Subclavian vein thrombosis: a continuing challenge.  Surgery. 1990;  108 1-9
    PubMedGoogle Scholar
  • 8 Mustafa S, Stein P D, Patel K C, Otten T R, Holmes R, Silbergleit A. Upper extremity deep venous thrombosis.  Chest. 2003;  123 1953-1956
    CrossrefPubMedGoogle Scholar
  • 9 Blom J W, Doggen C J, Osanto S, Rosendaal F R. Old and new risk factors for upper extremity deep venous thrombosis.  J Thromb Haemost. 2005;  3 2471-2478
    CrossrefPubMedGoogle Scholar
  • 10 Martinelli I, Battaglioli T, Bucciarelli P, Passamonti S M, Mannucci P M. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.  Circulation. 2004;  110 566-570
    CrossrefPubMedGoogle Scholar
  • 11 Nemcek Jr A A. Upper extremity deep venous thrombosis: interventional management.  Tech Vasc Interv Radiol. 2004;  7 86-90
    CrossrefPubMedGoogle Scholar
  • 12 Zell L, Kindermann W, Marschall F, Scheffler P, Gross J, Buchter A. Paget-Schroetter syndrome in sports activities-case study and literature review.  Angiology. 2001;  52 337-342
    PubMedGoogle Scholar
  • 13 Hendler M F, Meschengieser S S, Blanco A N et al.. Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects.  Am J Hematol. 2004;  76 330-337
    CrossrefPubMedGoogle Scholar
  • 14 Heron E, Lozinguez O, AlhencGelas M, Emmerich J, Fiessinger J N. Hypercoagulable states in primary upper-extremity deep vein thrombosis.  Arch Intern Med. 2000;  160 382-386
    CrossrefPubMedGoogle Scholar
  • 15 Vaya A, Mira Y, Mateo J et al.. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk.  Thromb Haemost. 2003;  89 452-457
    PubMedGoogle Scholar
  • 16 Girolami A, Prandoni P, Zanon E, Bagatella P, Girolami B. Venous thromboses of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs.  Blood Coagul Fibrinolysis. 1999;  10 455-457
    PubMedGoogle Scholar
  • 17 Hingorani A, Ascher E, Markevich N et al.. Risk factors for mortality in patients with upper extremity and internal jugular deep venous thrombosis.  J Vasc Surg. 2005;  41 476-478
    CrossrefPubMedGoogle Scholar
  • 18 Marinella M A, Kathula S K, Markert R J. Spectrum of upper-extremity deep venous thrombosis in a community teaching hospital.  Heart Lung. 2000;  29 113-117
    CrossrefPubMedGoogle Scholar
  • 19 Schmittling Z C, McLafferty R B, Bohannon W T, Ramsey D E, Hodgson K J. Characterization and probability of upper extremity deep venous thrombosis.  Ann Vasc Surg. 2004;  18 552-557
    CrossrefPubMedGoogle Scholar
  • 20 Van Rooden C J, Rosendaal F R, Meinders A E, Van Oostayen J A, Van Der Meer F J, Huisman M V. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis.  Haematologica. 2004;  89 201-206
    PubMedGoogle Scholar
  • 21 Chan W S, Ginsberg J S. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the ‘ART' behind the clot.  J Thromb Haemost. 2006;  4 1673-1677
    CrossrefPubMedGoogle Scholar
  • 22 David R, Zangwill L, Badarna M, Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure.  Ophthalmologica. 1988;  197 69-74
    CrossrefPubMedGoogle Scholar
  • 23 Hayreh S S, Zimmerman M B, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics.  Am J Ophthalmol. 1994;  117 429-441
    PubMedGoogle Scholar
  • 24 Prisco D, Marcucci R, Bertini L, Gori A M. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion.  Eur J Intern Med. 2002;  13 163-169
    PubMedGoogle Scholar
  • 25 Hayreh S S, Zimmerman B, McCarthy M J, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion.  Am J Ophthalmol. 2001;  131 61-77
    CrossrefPubMedGoogle Scholar
  • 26 Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study.  Arch Ophthalmol. 1996;  114 1243-1247
    PubMedGoogle Scholar
  • 27 Dodson P M, Galton D J, Hamilton A M, Blach R K. Retinal vein occlusion and the prevalence of lipoprotein abnormalities.  Br J Ophthalmol. 1982;  66 161-164
    PubMedGoogle Scholar
  • 28 Quinlan P M, Elman M J, Bhatt A K, Mardesich P, Enger C. The natural course of central retinal vein occlusion.  Am J Ophthalmol. 1990;  110 118-123
    PubMedGoogle Scholar
  • 29 Cugati S, Wang J J, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study.  Arch Ophthalmol. 2006;  124 726-732
    CrossrefPubMedGoogle Scholar
  • 30 Janssen M C, den Heijer M, Cruysberg J R, Wollersheim H, Bredie S J. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors.  Thromb Haemost. 2005;  93 1021-1026
    PubMedGoogle Scholar
  • 31 Arsene S, Delahousse B, Regina S, Le Lez M L, Pisella P J, Gruel Y. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age.  Thromb Haemost. 2005;  94 101-106
    PubMedGoogle Scholar
  • 32 Chua B, Kifley A, Wong T Y, Mitchell P. Homocysteine and retinal vein occlusion: a population-based study.  Am J Ophthalmol. 2005;  139 181-182
    CrossrefPubMedGoogle Scholar
  • 33 McGimpsey S J, Woodside J V, Bamford L et al.. Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype.  Invest Ophthalmol Vis Sci. 2005;  46 4712-4716
    CrossrefPubMedGoogle Scholar
  • 34 Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F. Plasma homocysteine and cysteine levels in retinal vein occlusion.  Invest Ophthalmol Vis Sci. 2006;  47 4067-4071
    CrossrefPubMedGoogle Scholar
  • 35 Cugati S, Wang J J, Knudtson M D et al.. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts.  Ophthalmology. 2007;  114 520-524
    CrossrefPubMedGoogle Scholar
  • 36 Ameri A, Bousser M G. Cerebral venous thrombosis.  Neurol Clin. 1992;  10 87-111
    PubMedGoogle Scholar
  • 37 Gates P C. Cerebral venous thrombosis. A retrospective review.  Aust N Z J Med. 1986;  16 766-770
    PubMedGoogle Scholar
  • 38 Ferro J M, Canhao P, Stam J, Bousser M G, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).  Stroke. 2004;  35 664-670
    CrossrefPubMedGoogle Scholar
  • 39 de Bruijn S F, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis.  Stroke. 1999;  30 484-488
    PubMedGoogle Scholar
  • 40 Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci P M. Hyperhomocysteinemia in cerebral vein thrombosis.  Blood. 2003;  102 1363-1366
    CrossrefPubMedGoogle Scholar
  • 41 Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems.  Am J Hematol. 2002;  70 126-132
    CrossrefPubMedGoogle Scholar
  • 42 Christopher R, Nagaraja D, Dixit N S, Narayanan C P. Anticardiolipin antibodies: a study in cerebral venous thrombosis.  Acta Neurol Scand. 1999;  99 121-124
    CrossrefPubMedGoogle Scholar
  • 43 Gadelha T, Andre C, Juca A A, Nucci M. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis.  Cerebrovasc Dis. 2005;  19 49-52
    CrossrefPubMedGoogle Scholar
  • 44 Bugnicourt J M, Roussel B, Tramier B, Lamy C, Godefroy O. Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case-control study.  J Neurol Neurosurg Psychiatry. 2007;  78 699-701
    PubMedGoogle Scholar
  • 45 Lichy C, Dong-Si T, Reuner K et al.. Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems.  J Neurol. 2006;  253 316-320
    CrossrefPubMedGoogle Scholar
  • 46 Kumar S, Sarr M G, Kamath P S. Mesenteric venous thrombosis.  N Engl J Med. 2001;  345 1683-1688
    PubMedGoogle Scholar
  • 47 Valla D C, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management.  J Hepatol. 2000;  32 865-871
    CrossrefPubMedGoogle Scholar
  • 48 Janssen H L, Meinardi J R, Vleggaar F P et al.. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.  Blood. 2000;  96 2364-2368
    PubMedGoogle Scholar
  • 49 Amitrano L, Brancaccio V, Guardascione M A et al.. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis.  Am J Gastroenterol. 2001;  96 146-149
    CrossrefPubMedGoogle Scholar

Federico LussanaM.D. 

Department of Vascular Medicine, Academic Medical Center, University of Amsterdam

Meibergdreef 9 1105 AZ Amsterdam, The Netherlands

Email: federico.lussana@ao-sanpaolo.it

      >